Enflurane or 2-chloro-1,1,2,-trifluoroethyl-difluoromethyl ether (CHF2OCF2CHFCl)) is a halogenated inhaled anesthetic that can now be considered as a chapter of the history of anesthesia. It was synthesized by Ross Terrell, in 1963. It was approved by the Food and Drug Administration (FDA) for the induction and maintenance of general anesthesia (GA), becoming available in the United States in 1972. Between the late '60s and most of the '80s, it was the most widely used inhalation. However, its usage has decreased in favor of newer halogenated anesthetics such as isoflurane  (enflurane is a structural isomer of isoflurane), sevoflurane, and desflurane which show a better pharmacokinetic profile (faster induction and emergence times) and are less burdened, compared to enflurane, with side effects, especially in terms of nephrotoxicity and pro-convulsant activity. Furthermore, enflurane has been used to treat refractory status asthmasticus, though this usage is not FDA approved.
The mechanism of action of enflurane and other halogenated inhaled anesthetics is still poorly understood. The hypothesis is that these agents act on different ion channels within the nervous system by blocking excitatory channels and augmenting inhibitory channels. In particular, volatile anesthetics can depress ventral horn neurons, causing immobilization. For enflurane, 30% of depressant effects on the spinal cord are mediated by the gamma-aminobutyric acid type A (GABA-A) receptor, and glycine receptors mediate 20 % of the effects.
Enflurane is a clear, colorless liquid at room temperature, requiring a vaporizer for administration. It is then inhaled via a face mask. Enflurane is a non-flammable, nonexplosive liquid. The boiling point is 56.5 degrees C at 760 mm Hg, and the vapor pressure (in mm Hg) is 175 at 20 degrees C, 218 at 25 degrees C, and 345 at 36 degrees C. The delivery of continuous enflurane causes drug accumulation within the alveoli. Through gas exchange in the lungs, enflurane is carried on red blood cells and distributed to the rest of the body. The minimal alveolar concentration (MAC) of enflurane is 1.68%in pure oxygen, 0.57 in 70% nitrous oxide, 30% oxygen, and 1.17 in 30% nitrous oxide, 70% oxygen. The MAC-Awake (the concentration at which appropriate responses to commands are loss) that produces ). Blood-gas partition in adults is 2.07 and 1.78 in children, at 37 degrees. The blood-gas partition correlates with serum albumin and triglyceride concentrations, which would explain the lower partition as children have less serum albumin and triglyceride. In particular, because the blood-gas partition coefficient slightly lower than that of halothane, induction and awakening are relatively slow. Certainly, induction and emergence times are slower than other halogenates such as desflurane (blood-gas coefficient 0.47) or sevoflurane (0.65).
Induction. A hypnotic dose of a short-acting barbiturate or propofol followed by the mixture of the inhaled anesthetic with oxygen and air can be used to induce the loss of consciousness (LOC). In general, enflurane concentrations from 2.0% to 4.5% cause surgical anesthesia in 7 to 10 minutes. When using enflurane to induce LOC, the recommendation is to start the induction phase with enflurane at a concentration of 0.5% and gradually increasing by another 0.5% every few respiratory acts until reaching the level of surgical anesthesia. The concentration at this level must be less than 4%. The inhaled agent has a mild, sweet odor and may induce a mild stimulus to salivation or tracheobronchial secretions. Again, pharyngeal and laryngeal reflexes are readily obtunded.
Maintenance. Surgical anesthesia levels are maintainable with 0.5 to 3% enflurane concentrations. Maintenance concentrations should not exceed 3.0%.
Emergence. The concentration of enflurane can be reduced to 0.5% towards the end of the surgery or suspended at the beginning of the surgical suture.
Hemodynamic effects. The administration of enflurane has been known to decreases systemic vascular resistance. This effect causes decreased blood pressure. Enflurane is also known to cause a concentration-dependent decrease in heart and an increase in left atrial pressure.
Respiratory effects. Inhaled anesthetics have shown to have potent bronchodilator properties. Along with bronchodilation, inhaled anesthetics have to decrease airway responsiveness and reduce histamine-induced bronchospasm. It is unknown the exact mechanism to dilate the airway. However, the current theories are direct action on airway smooth muscle via diffusion to airway wall, systemic distribution of the gas via circulation, and central neurologic action.
Neurological effects. Enflurane is known to increase cerebral blood volume in comparison to halothane. The metabolism of enflurane has also shown to increase cerebral blood flow, especially when anesthesia is at the level of frequent spikes and suppression on electroencephalogram (EEG). As a result of the increased blood flow, enflurane has demonstrated to decrease cerebral vascular resistance and cerebral metabolic rate for oxygen. The thought was that enflurane is pro-convulsant due to the GABA-ergic effect of inhaled anesthetics. On EEG, enflurane causes high-amplitude sharp waves, which are called paroxysmal epileptiform discharges. Researchers theorize that enflurane causes increased neuronal inhibition in the cortex, so any small amount of excitation would cause electrical discharges.
Other effects. Along with the mentioned effect, enflurane can also cause cardiac arrhythmias, postoperative nausea and vomiting, respiratory irritation, and agitation (emergence delirium) or postoperative delirium.
Like many inhaled anesthetics, enflurane is contraindicated for a patient who has a personal history or family history of malignant hyperthermia. Depending on hospital policy, either the machine will be cleaned so there would be no lingering traces of any inhaled gas in the machine or a different machine used only for patients with malignant hyperthermia will be in the operating room.
Generally, it is contraindicated in pregnancy or during breastfeeding and in patients with convulsive disorders.
There are no specific guidelines on monitoring enflurane. However, guidelines set by the American Society of Anesthesiologists (ASA) recommend monitoring for consciousness, pulmonary ventilation, oxygenation, and hemodynamics. Intraoperatively, the patient is monitored by using pulse oximetry, electrocardiography, continuous blood pressure device, temperature monitor, inspired and expired oxygen levels, inspired and expired volatile anesthetic levels, carbon dioxide levels, and airway pressure. If the surgery requires patient paralysis, peripheral nerve stimulation will be used. Though not in the recommendations, anesthesiologists have used the bispectral index (BIS) to monitor the depth of anesthesia to prevent intraoperative awareness.
Like many inhaled anesthetic, enflurane has associated adverse effects. Amongst the effects are hepatotoxicity, nephrotoxicity, and neurotoxicity.
Hepatotoxicity. Enflurane has shown minor elevations in serum aminotransferase levels (5- to 50-fold) 1 to 2 weeks after surgery and anesthesia. Furthermore, jaundice has been reported 2 to 21 days following surgery. There is also an elevation in alkaline phosphatase and gamma-glutamyl transpeptidase levels. Rarely, enflurane causes rash and eosinophilia after a day of fever. The mechanism of injury is thought to be similar to halothane-associated hepatotoxicity. Enflurane is metabolized by liver enzyme CYP2E1 to trifluoroacetate reactive intermediate, which binds to several proteins.
Nephrotoxicity. Nephrotoxicity from enflurane use is associated with high doses of the drug. This anesthetic can cause significant renal structure damage as well as transient renal functional impairment. However, there is greater potential for toxicity when there is already renal impairment. The mechanism of injury appears to be due to increased concentration from an enflurane metabolite, inorganic fluoride. Approximately 2.4% are fluorinated urinary metabolites, of which 0.5% as fluorine inorganic and 1.9% as organic fluorine. Along with decreased ability to eliminate inorganic fluoride, there is an increased urine flow rate and more significant damage in the proximal convoluted tubule cells.
Neurotoxicity. Currently, no anesthetic is contraindicated for pregnancy due to neurotoxicity. However, there is very limited research on the effects of volatile anesthetics on developing brains. Exposure to volatile anesthetic theoretically causes acute neurotoxicity and later defects in learning and memory during the postnatal period. Other subtle neurotoxicity includes abnormal fear response and social interactions. The theorized mechanism of injury includes reactive oxygen species stress, growth or nutrient signaling, and direct neuronal modulation. Early studies have shown potential neurotoxicity via N-methyl-D-aspartate (NMDA) receptor antagonism and potentiation of GABA signal transduction. A different study showed that volatile anesthetics induce interleukin 6 (IL-6) mRNA. The cytokine may affect neuronal precursor cells, which would later cause learning impairments in the fetus.
To maintain patient safety, enflurane administration should only be by trained anesthesiologists or healthcare professionals certified in anesthesia. It is essential to encourage anyone involved in the direct care of the patient to speak up about any concerns they have about the patient's safety. Having a team meeting with the surgeon, anesthesiologist, and all patient care personnel involved directly with the specific patient will help to better outcomes of surgery. Communication between surgeons and anesthesiologists is required to determine the timing of emergence from the anesthesia. Following the surgery, anesthesia personnel can give a thorough hand-off to nurses in the post-anesthesia care unit to help with the emergence of enflurane. [Level 5]
|||Enflurane 2012; [PubMed PMID: 31643793]|
|||Burburan SM,Xisto DG,Rocco PR, Anaesthetic management in asthma. Minerva anestesiologica. 2007 Jun; [PubMed PMID: 17115010]|
|||Grasshoff C,Antkowiak B, Effects of isoflurane and enflurane on GABAA and glycine receptors contribute equally to depressant actions on spinal ventral horn neurones in rats. British journal of anaesthesia. 2006 Nov; [PubMed PMID: 16973644]|
|||Chandan G,Cascella M, Gas Laws and Clinical Application . 2020 Jan [PubMed PMID: 31536199]|
|||Lerman J,Gregory GA,Willis MM,Eger EI 2nd, Age and solubility of volatile anesthetics in blood. Anesthesiology. 1984 Aug; [PubMed PMID: 6465597]|
|||Sahlman L,Henriksson BA,Martner J,Ricksten SE, Effects of halothane, enflurane, and isoflurane on coronary vascular tone, myocardial performance, and oxygen consumption during controlled changes in aortic and left atrial pressure. Studies on isolated working rat hearts in vitro. Anesthesiology. 1988 Jul; [PubMed PMID: 3389543]|
|||Mondoñedo JR,McNeil JS,Amin SD,Herrmann J,Simon BA,Kaczka DW, Volatile Anesthetics and the Treatment of Severe Bronchospasm: A Concept of Targeted Delivery. Drug discovery today. Disease models. 2015 Spring; [PubMed PMID: 26744597]|
|||Artru AA, Relationship between cerebral blood volume and CSF pressure during anesthesia with halothane or enflurane in dogs. Anesthesiology. 1983 Jun; [PubMed PMID: 6859583]|
|||Sakabe T,Maekawa T,Fujii S,Ishikawa T,Tateishi A,Takeshita H, Cerebral circulation and metabolism during enflurane anesthesia in humans. Anesthesiology. 1983 Dec; [PubMed PMID: 6650909]|
|||Sleigh JW,Vizuete JA,Voss L,Steyn-Ross A,Steyn-Ross M,Marcuccilli CJ,Hudetz AG, The electrocortical effects of enflurane: experiment and theory. Anesthesia and analgesia. 2009 Oct; [PubMed PMID: 19762755]|
|||Stachnik J, Inhaled anesthetic agents. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2006 Apr 1; [PubMed PMID: 16554286]|
|||Cascella M,Muzio MR,Bimonte S,Cuomo A,Jakobsson JG, Postoperative delirium and postoperative cognitive dysfunction: updates in pathophysiology, potential translational approaches to clinical practice and further research perspectives. Minerva anestesiologica. 2018 Feb [PubMed PMID: 28984099]|
|||Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002 Apr; [PubMed PMID: 11964611]|
|||Bispectral index monitor: an evidence-based analysis. Ontario health technology assessment series. 2004; [PubMed PMID: 23074459]|
|||Cascella M, Mechanisms underlying brain monitoring during anesthesia: limitations, possible improvements, and perspectives. Korean journal of anesthesiology. 2016 Apr [PubMed PMID: 27066200]|
|||Safari S,Motavaf M,Seyed Siamdoust SA,Alavian SM, Hepatotoxicity of halogenated inhalational anesthetics. Iranian Red Crescent medical journal. 2014 Sep; [PubMed PMID: 25593732]|
|||Cousins MJ,Fulton A,David W,Haynes G,Whitehead R, Enflurane nephrotoxicity and pre-existing renal dysfunction. Anaesthesia and intensive care. 1978 Nov; [PubMed PMID: 736249]|
|||Cascella M,Bimonte S, The role of general anesthetics and the mechanisms of hippocampal and extra-hippocampal dysfunctions in the genesis of postoperative cognitive dysfunction. Neural regeneration research. 2017 Nov [PubMed PMID: 29239315]|
|||Johnson SC,Pan A,Li L,Sedensky M,Morgan P, Neurotoxicity of anesthetics: Mechanisms and meaning from mouse intervention studies. Neurotoxicology and teratology. 2019 Jan - Feb; [PubMed PMID: 30472095]|
|||Mellon RD,Simone AF,Rappaport BA, Use of anesthetic agents in neonates and young children. Anesthesia and analgesia. 2007 Mar; [PubMed PMID: 17312200]|
|||Hirotsu A,Iwata Y,Tatsumi K,Miyai Y,Matsuyama T,Tanaka T, Maternal exposure to volatile anesthetics induces IL-6 in fetal brains and affects neuronal development. European journal of pharmacology. 2019 Nov 15; [PubMed PMID: 31545984]|
|||Sexton JB,Makary MA,Tersigni AR,Pryor D,Hendrich A,Thomas EJ,Holzmueller CG,Knight AP,Wu Y,Pronovost PJ, Teamwork in the operating room: frontline perspectives among hospitals and operating room personnel. Anesthesiology. 2006 Nov; [PubMed PMID: 17065879]|
|||Cascella M, Emergence from anesthesia: a winding way back. Anaesthesiology intensive therapy. 2018 [PubMed PMID: 29953576]|